Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC.

Authors:
Tung PH; Chiu TH; Huang AC; Ju JS; Huang CH and 8 more

Journal:
Ther Adv Med Oncol

Publication Year: 2024

DOI:
10.1177/17588359231222604

PMCID:
PMC10799606

PMID:
38249338

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Ther Adv Med Oncol

Abbreviation: Ther Adv Med Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-an…
Petrelli F; Antista M; Marra F and 8 more (2024) - Transparency Score: 3/6
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluati…
Sepe P; Procopio G; Pircher CC and 16 more (2024) - Transparency Score: 4/6
A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line …
Yu N; Huang S; Zhang Z and 9 more (2024) - Transparency Score: 4/6
Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer.
Bai Q; Shi X; Zhou X and 3 more (2024) - Transparency Score: 3/6
Chronological improvement of survival in patients with advanced gastric cancer over 15 years.
Ogata T; Narita Y; Oze I and 14 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"C-HSK received speaker honoraria from AstraZeneca, Boehringer Ingelheim, Roche, Pfizer, Eli Lilliy, Novartis, OnO Pharma, Chugai, Merck, Janssen Pharma, Takeda, and Guardant Health. C-HSK provided consultation for AstraZeneca, Boehringer Ingelheim, Eli Lilliy, Merck, Chugai, Takeda, Novartis, and Guardant Health. None of the other authors have any conflict of interest to disclose."

Evidence found in paper:

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study received funding support from Chang Gung Medical Foundation CORPG3J0332; CORPG3 J0333; CMRPG5M0051."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025